BP, Nuseed Enter Into 10-Year Strategic Agreement Enabling Nuseed To Accelerate Expansion Of Nuseed Carinata Sustainable Production Program

-Reuters

byBenzinga Newsdesk

February 1, 2022

1 minute read

-Reuters

HSBC Partners With Oracle To Accelerate Technology Transformation; Under Multi-Year Agreement, HSBC Will Upgrade And Migrate Select Database Systems To Oracle Exadata Cloud@Customer

By Benzinga Newsdesk

October 18, 8:11 AM

Oracle CloudWorld -- Oracle and HSBC, one of the world's largest financial services organizations, today announced a strategic collaboration to accelerate the bank's digital transformation. Under

HSBC

Keybanc Maintains Overweight on Broadcom, Raises Price Target to $720

By Benzinga Newsdesk

March 4, 5:59 AM

Keybanc analyst John Vinh maintains Broadcom (NASDAQ:AVGO) with a Overweight and raises the price target from $710 to $720.

AVGO

Arlington Asset Q2 Adj. EPS $0.07 Beats $0.04 Estimate, Sales $5.09M Beat $3.21M Estimate

By Benzinga Newsdesk

August 3, 5:25 PM

Arlington Asset (NYSE:AAIC) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.04 by 75 percent. This is a 600 percent increase over earnings of $0.01 per share from the same

AAIC

Stifel Initiates Coverage On Relay Therapeutics with Buy Rating, Announces Price Target of $40

By Benzinga Newsdesk

September 2, 4:55 AM

Stifel analyst Bradley Canino initiates coverage on Relay Therapeutics (NASDAQ:RLAY) with a Buy rating and announces Price Target of $40.

RLAY

BP, Nuseed Enter Into 10-Year Strategic Agreement Enabling Nuseed To Accelerate Expansion Of Nuseed Carinata Sustainable Production Program

Related Posts

HSBC Partners With Oracle To Accelerate Technology Transformation; Under Multi-Year Agreement, HSBC Will Upgrade And Migrate Select Database Systems To Oracle Exadata Cloud@Customer

Keybanc Maintains Overweight on Broadcom, Raises Price Target to $720

Arlington Asset Q2 Adj. EPS $0.07 Beats $0.04 Estimate, Sales $5.09M Beat $3.21M Estimate

Stifel Initiates Coverage On Relay Therapeutics with Buy Rating, Announces Price Target of $40